Introduction
Growth hormone peptides are among the most popular classes of supplements in both the longevity and performance worlds. CJC-1295 is one such peptide that is available in two different forms- one has a chemical addition called DAC (Drug Affinity Complex), while the other does not. Modified peptides without DAC are typically referred to as CJC-1295 without DAC or, most accurately, Mod GRF 1-29.
Both of these peptides might still sound very similar, but they act very differently once they are inside the body. One of them causes a prolonged, steady increase in growth hormone levels, and the other creates a short, sharp pulse that closely resembles the body’s natural growth hormone release pattern. This difference between these peptides is quite huge.
This leads to the question- why would CJC-1295 without DAC, with its shorter half-life and more frequent dosing schedule, be viewed as the more physiologically favourable option by many researchers and clinicians? To understand that, a deep dive into how growth hormone is actually released in the body is needed.
What is CJC-1295 without DAC (Mod GRF 1-29)?

CJC-1295 without DAC (also known as Mod GRF 1-29) is a modified, stabilized fragment of growth hormone-releasing hormone (GHRH) that increases pulsatile growth hormone (GH) release, supporting muscle growth, fat metabolism, and recovery. GHRH is the hormone that the hypothalamus naturally produces to signal the pituitary gland to release growth hormone. The “Mod” denotes a few amino acid modifications that help the peptide resist enzymatic breakdown. The 1-29 refers to this peptide using only the first 29 amino acids of the complete GHRH molecule. The rest of the molecule has been removed because the truncated form maintains 100% biological activity.
Unlike the DAC version, Mod GRF 1-29 lacks the binding agent DAC, which greatly extends a peptide’s half-life. As a result, Mod GRF 1-29 clears from the bloodstream within approximately 30 minutes. That is not a downside. On the contrary, it is the entire reason to take Mod GRF 1-29.
New to peptide therapy? Explore our complete Peptide & Bioregulator series to understand how different peptides support longevity, metabolism, recovery, and healthy aging.
What is the Mechanism of Action?
GH is not released continuously throughout the day. It is released in pulses, mostly during deep sleep, with smaller pulses occurring around exercise and during fasting. This pulsatile pattern exists for a biological reason. The pituitary gland and its downstream systems only like to be stimulated in short bursts followed by periods of rest.
Mod GRF 1-29 binds to GHRH receptors on the pituitary gland, which triggers an immediate release of GH from the pituitary gland. Since the peptide clears out quickly, there is a sharp and short GH pulse that mimics the natural signaling of a healthy hypothalamus.
CJC-1295 with DAC is completely opposite. The DAC modification binds to albumin in the blood, which increases the half-life of the peptide to about eight days. Instead of one short pulse, there is a continuous stimulation of the GHRH receptors over an extended period. This creates a sustained elevation of GH (and more specifically insulin-like growth factor 1 or IGF-1) rather than a distinct pulse.
Why Continuous Stimulation May Not Be the Better Strategy
Continuous stimulation might sound more effective on paper. More stimulation, more growth hormone, more benefit. However, the endocrine system does not always work that way. Pulsatility, as mentioned, carries a biological meaning.
GHRH-responsive somatotroph cells in the pituitary gland require receptor sensitivity in order to respond appropriately to GHRH signals. Continuous stimulation of GHRH receptors (as opposed to intermittent pulses) can cause receptor desensitization to occur. Over a period of time, cells that are exposed to continuous signaling can downregulate their receptors as a protective mechanism. This may further blunt the pituitary gland’s natural response.
Then there is feedback regulation to consider. GH release is governed by a negative feedback loop that involves the hormone somatostatin, which inhibits GH release. In a healthy pulsatile system, GH rises sharply, IGF-1 responds, and somatostatin steps in to bring the system back to normal before the next natural pulse. When GH and IGF-1 remain elevated for days at a time, as happens with the DAC version, this feedback loop is disrupted in a way that does not reflect normal physiology.
Mod GRF 1-29 avoids this problem structurally. As it clears out of the body quickly, it allows the pituitary gland to reset between doses, preserving the natural rhythm of the hypothalamic-pituitary axis instead of overriding it.
How Combining With a GHRP Enhances the Pulse

Mod GRF 1-29 is often co-administered with a growth hormone-releasing peptide (GHRP) like ipamorelin or GHRP-2. GHRH and GHRPs bind to completely different receptors. GHRH analogs, including Mod GRF 1-29, bind directly to the GHRH receptor. GHRPs bind to the ghrelin receptor and also inhibit the release of somatostatin, which normally limits GH release.
Stimulation of both these pathways leads to a much greater GH pulse than either of these compounds producing alone, yet it is still only one single, time-limited pulse rather than a sustained elevation. This synergy is one of the main reasons why the no-DAC version is preferred over the DAC version in most research and clinical protocols that aim to maintain natural signaling patterns.
Dosing and Administration
Since Mod GRF 1-29 has a short half-life of about 30 minutes, it is usually administered multiple times per week, often once or twice daily. It comes in lyophilized form that needs to be reconstituted with bacteriostatic water before use. The peptide is administered via subcutaneous route 5 days a week followed by 2 days off, for 8-12 weeks. As previously stated, due to its extended half-life, the DAC version of the peptide is commonly given only once or twice per week.
The frequent dosing schedule required with the no-DAC version may seem undesirable when compared to once-weekly injections, but it is necessary in order to achieve the physiologically natural result. Matching the dosing pattern to the body’s natural pulse timing is part of the mechanism, not a drawback of it.
What Are the Considerations and Safety Notes?

Side effects of GHRH analogs are usually mild and include temporary flushing, mild irritation at the injection site, and sometimes dizziness shortly after injection. Mod GRF 1-29 does not keep GH and IGF-1 levels constantly elevated for an extended period, so the theoretical concerns linked to prolonged GH and IGF-1 elevation, including insulin sensitivity changes, are generally considered lower with the no-DAC version than the DAC version. However, this has not been studied long-term with either of these peptide versions, which is why it is important to only use peptides under the care of a professional who can monitor you for unwanted side effects.
Before considering any peptide protocol, understanding your hormones, metabolism, sleep quality, stress levels, and nutrient status is essential. Book your Root Cause Analysis to discover whether growth hormone support is appropriate for your biology.
Key Takeaway
Constantly flooding the body with GH is not how it is supposed to function. GH release is designed to pulsate in bursts that quickly rise and fall. When used continuously, most hormones cause receptor sensitivity to that hormone to diminish over time. Your body is accustomed to the pulsatile release of GH, so when you blunt that pulse, you force your body to operate under unfamiliar terms. CJC-1295 without DAC, or Mod GRF 1-29, honours the body’s natural blueprint. By mimicking the pulse that your body is already built around, rather than forcing it to rely on artificial means of release, you are working within your biology, not against it. If maintaining that natural pulse is your priority and you would like to preserve long-term receptor sensitivity, then the shorter-acting peptide variant is right for you, even if it means more frequent injections.
References
- Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536
- Alba, M., Fintini, D., Sagazio, A., Lawrence, B., Castaigne, J. P., Frohman, L. A., & Salvatori, R. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 291(6), E1290–E1294. https://doi.org/10.1152/ajpendo.00201.2006













